Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer

Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly nam...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Integrative cancer therapies 2013-09, Vol.12 (5), p.414-422
Hauptverfasser: Xu, Yan, Zhao, Ai Guang, Li, Zhao Yan, Zhao, Gang, Cai, Yong, Zhu, Xiao Hong, Cao, Ni Da, Yang, Jin Kun, Zheng, Jian, Gu, Yin, Han, Ying Ying, Zhu, Ying Jie, Yang, Jin Zu, Gao, Feng, Wang, Qiang
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 422
container_issue 5
container_start_page 414
container_title Integrative cancer therapies
container_volume 12
creator Xu, Yan
Zhao, Ai Guang
Li, Zhao Yan
Zhao, Gang
Cai, Yong
Zhu, Xiao Hong
Cao, Ni Da
Yang, Jin Kun
Zheng, Jian
Gu, Yin
Han, Ying Ying
Zhu, Ying Jie
Yang, Jin Zu
Gao, Feng
Wang, Qiang
description Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.
doi_str_mv 10.1177/1534735412450512
format Article
fullrecord <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_1428773210</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1534735412450512</sage_id><sourcerecordid>1428773210</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</originalsourceid><addsrcrecordid>eNp1UctOwzAQtBCI8rpzQj7CIWDHcZweoaItUhFILYJb5Djr1ii1i51U4h_4aFwKHJA47e7s7Eg7g9ApJZeUCnFFOcsE4xlNM044TXfQAeU8TfI-f9nd9CxLNvseOgzhlZCUkpzvo16aioLyjB-gj2nn12YtG3wDFrRpsdN45mVtWuNshAcLYyEAHoOv4ngPtVERwefyBxo6v-waibXz-M6uzdx52Ro7x9NVA2AvvhaPEQLbBvxs2gW-rtfSKqjxSIbWG4UHm9Efoz0tmwAn3_UIPQ1vZ4NxMnkY3Q2uJ4liot8mkihOcl3VOecVA6CaQAEK0lpwkRUiPpmpivR1VQiZKy2YkKRgEkCAEhzYETrf6q68e-sgtOXSBAVNIy24LpQ0SwshWHQrUsmWqrwLwYMuV94spX8vKSk3GZR_M4gnZ9_qXbWE-vfgx_RISLaEIOdQvrrOR6PD_4KfD36Pqw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428773210</pqid></control><display><type>article</type><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><source>Sage Journals GOLD Open Access 2024</source><creator>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</creator><creatorcontrib>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</creatorcontrib><description>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</description><identifier>ISSN: 1534-7354</identifier><identifier>EISSN: 1552-695X</identifier><identifier>DOI: 10.1177/1534735412450512</identifier><identifier>PMID: 22781545</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adenocarcinoma - drug therapy ; Adenocarcinoma - mortality ; Adenocarcinoma - pathology ; Adult ; Aged ; Aged, 80 and over ; Disease Progression ; Drugs, Chinese Herbal - therapeutic use ; Female ; Humans ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Spleen - drug effects ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Survival Analysis ; Young Adult</subject><ispartof>Integrative cancer therapies, 2013-09, Vol.12 (5), p.414-422</ispartof><rights>The Author(s) 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</citedby><cites>FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1534735412450512$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1534735412450512$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,861,21947,27834,27905,27906,44926,45314</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/1534735412450512?utm_source=summon&amp;utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22781545$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Yan</creatorcontrib><creatorcontrib>Zhao, Ai Guang</creatorcontrib><creatorcontrib>Li, Zhao Yan</creatorcontrib><creatorcontrib>Zhao, Gang</creatorcontrib><creatorcontrib>Cai, Yong</creatorcontrib><creatorcontrib>Zhu, Xiao Hong</creatorcontrib><creatorcontrib>Cao, Ni Da</creatorcontrib><creatorcontrib>Yang, Jin Kun</creatorcontrib><creatorcontrib>Zheng, Jian</creatorcontrib><creatorcontrib>Gu, Yin</creatorcontrib><creatorcontrib>Han, Ying Ying</creatorcontrib><creatorcontrib>Zhu, Ying Jie</creatorcontrib><creatorcontrib>Yang, Jin Zu</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Wang, Qiang</creatorcontrib><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><title>Integrative cancer therapies</title><addtitle>Integr Cancer Ther</addtitle><description>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adenocarcinoma - mortality</subject><subject>Adenocarcinoma - pathology</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Disease Progression</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine, Chinese Traditional</subject><subject>Middle Aged</subject><subject>Spleen - drug effects</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Survival Analysis</subject><subject>Young Adult</subject><issn>1534-7354</issn><issn>1552-695X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1UctOwzAQtBCI8rpzQj7CIWDHcZweoaItUhFILYJb5Djr1ii1i51U4h_4aFwKHJA47e7s7Eg7g9ApJZeUCnFFOcsE4xlNM044TXfQAeU8TfI-f9nd9CxLNvseOgzhlZCUkpzvo16aioLyjB-gj2nn12YtG3wDFrRpsdN45mVtWuNshAcLYyEAHoOv4ngPtVERwefyBxo6v-waibXz-M6uzdx52Ro7x9NVA2AvvhaPEQLbBvxs2gW-rtfSKqjxSIbWG4UHm9Efoz0tmwAn3_UIPQ1vZ4NxMnkY3Q2uJ4liot8mkihOcl3VOecVA6CaQAEK0lpwkRUiPpmpivR1VQiZKy2YkKRgEkCAEhzYETrf6q68e-sgtOXSBAVNIy24LpQ0SwshWHQrUsmWqrwLwYMuV94spX8vKSk3GZR_M4gnZ9_qXbWE-vfgx_RISLaEIOdQvrrOR6PD_4KfD36Pqw</recordid><startdate>201309</startdate><enddate>201309</enddate><creator>Xu, Yan</creator><creator>Zhao, Ai Guang</creator><creator>Li, Zhao Yan</creator><creator>Zhao, Gang</creator><creator>Cai, Yong</creator><creator>Zhu, Xiao Hong</creator><creator>Cao, Ni Da</creator><creator>Yang, Jin Kun</creator><creator>Zheng, Jian</creator><creator>Gu, Yin</creator><creator>Han, Ying Ying</creator><creator>Zhu, Ying Jie</creator><creator>Yang, Jin Zu</creator><creator>Gao, Feng</creator><creator>Wang, Qiang</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201309</creationdate><title>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</title><author>Xu, Yan ; Zhao, Ai Guang ; Li, Zhao Yan ; Zhao, Gang ; Cai, Yong ; Zhu, Xiao Hong ; Cao, Ni Da ; Yang, Jin Kun ; Zheng, Jian ; Gu, Yin ; Han, Ying Ying ; Zhu, Ying Jie ; Yang, Jin Zu ; Gao, Feng ; Wang, Qiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-a0c506fbd655b3ee1f0e8ece2d7574871064cb09fb87a6cf737a083aee7ec75e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adenocarcinoma - mortality</topic><topic>Adenocarcinoma - pathology</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Disease Progression</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine, Chinese Traditional</topic><topic>Middle Aged</topic><topic>Spleen - drug effects</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Survival Analysis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Yan</creatorcontrib><creatorcontrib>Zhao, Ai Guang</creatorcontrib><creatorcontrib>Li, Zhao Yan</creatorcontrib><creatorcontrib>Zhao, Gang</creatorcontrib><creatorcontrib>Cai, Yong</creatorcontrib><creatorcontrib>Zhu, Xiao Hong</creatorcontrib><creatorcontrib>Cao, Ni Da</creatorcontrib><creatorcontrib>Yang, Jin Kun</creatorcontrib><creatorcontrib>Zheng, Jian</creatorcontrib><creatorcontrib>Gu, Yin</creatorcontrib><creatorcontrib>Han, Ying Ying</creatorcontrib><creatorcontrib>Zhu, Ying Jie</creatorcontrib><creatorcontrib>Yang, Jin Zu</creatorcontrib><creatorcontrib>Gao, Feng</creatorcontrib><creatorcontrib>Wang, Qiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Integrative cancer therapies</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Xu, Yan</au><au>Zhao, Ai Guang</au><au>Li, Zhao Yan</au><au>Zhao, Gang</au><au>Cai, Yong</au><au>Zhu, Xiao Hong</au><au>Cao, Ni Da</au><au>Yang, Jin Kun</au><au>Zheng, Jian</au><au>Gu, Yin</au><au>Han, Ying Ying</au><au>Zhu, Ying Jie</au><au>Yang, Jin Zu</au><au>Gao, Feng</au><au>Wang, Qiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer</atitle><jtitle>Integrative cancer therapies</jtitle><addtitle>Integr Cancer Ther</addtitle><date>2013-09</date><risdate>2013</risdate><volume>12</volume><issue>5</issue><spage>414</spage><epage>422</epage><pages>414-422</pages><issn>1534-7354</issn><eissn>1552-695X</eissn><abstract>Background. Traditional Chinese herbal medicine (TCHM) is widely used for advanced gastric cancer (AGC) in China. In this study, the authors analyzed the prognostic factors of selected patients with AGC, and further studied the efficacy of TCHM (a herbal formula for invigorating spleen, formerly named Wei Chang’ An) on AGC. Methods. Patients with uncured AGC were prospectively enrolled. All patients were enrolled to either the TCHM group or non-TCHM group. TCHM was administered orally to the patients in the TCHM group for 3 months or more. Cox regression analysis was performed to determine survival trends adjusted for clinical and demographic factors. Kaplan–Meier curves were used to assess the differences in survival time. Results. There were a total of 399 eligible patients with histologically confirmed adenocarcinoma of the stomach from 2001 to 2009. In the overall group, Cox regression analysis suggested that histological type (P = .016), radiotherapy (P = .000), cycle of chemotherapy (P = .000), and TCHM (P = .000) were independent prognostic factors. In a stratification analysis of stage for 213 patients who received 3 or more cycles of chemotherapy, there was a significant increase in median overall survival from 14.0 (non-TCHM group) to 20.0 (TCHM group) months (hazard ratio [HR] = 0.538, 95% confidence interval [CI] 0.385-0.750, P = .000). Among 186 patients who did not receive chemotherapy, but best supportive care, there was a significant increase in median overall survival from 7.0 (non-TCHM group) to 14.8 (TCHM group) months (HR = 0.443, 95% CI = 0.299-0.657, P = .000). Conclusions. TCHM has an important potential value for improving the prognosis of patients with AGC.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>22781545</pmid><doi>10.1177/1534735412450512</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1534-7354
ispartof Integrative cancer therapies, 2013-09, Vol.12 (5), p.414-422
issn 1534-7354
1552-695X
language eng
recordid cdi_proquest_miscellaneous_1428773210
source Sage Journals GOLD Open Access 2024
subjects Adenocarcinoma - drug therapy
Adenocarcinoma - mortality
Adenocarcinoma - pathology
Adult
Aged
Aged, 80 and over
Disease Progression
Drugs, Chinese Herbal - therapeutic use
Female
Humans
Male
Medicine, Chinese Traditional
Middle Aged
Spleen - drug effects
Stomach Neoplasms - drug therapy
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Survival Analysis
Young Adult
title Survival Benefit of Traditional Chinese Herbal Medicine (a Herbal Formula for Invigorating Spleen) for Patients With Advanced Gastric Cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A42%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20Benefit%20of%20Traditional%20Chinese%20Herbal%20Medicine%20(a%20Herbal%20Formula%20for%20Invigorating%20Spleen)%20for%20Patients%20With%20Advanced%20Gastric%20Cancer&rft.jtitle=Integrative%20cancer%20therapies&rft.au=Xu,%20Yan&rft.date=2013-09&rft.volume=12&rft.issue=5&rft.spage=414&rft.epage=422&rft.pages=414-422&rft.issn=1534-7354&rft.eissn=1552-695X&rft_id=info:doi/10.1177/1534735412450512&rft_dat=%3Cproquest_AFRWT%3E1428773210%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428773210&rft_id=info:pmid/22781545&rft_sage_id=10.1177_1534735412450512&rfr_iscdi=true